These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 10779805

  • 1. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.
    Bergmann-Leitner ES, Abrams SI.
    J Immunol; 2000 May 01; 164(9):4941-54. PubMed ID: 10779805
    [Abstract] [Full Text] [Related]

  • 2. Influence of interferon gamma on modulation of Fas expression by human colon carcinoma cells and their subsequent sensitivity to antigen-specific CD8+ cytotoxic T lymphocyte attack.
    Bergmann-Leitner ES, Abrams SI.
    Cancer Immunol Immunother; 2000 Jul 01; 49(4-5):193-207. PubMed ID: 10941902
    [Abstract] [Full Text] [Related]

  • 3. Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes.
    Bergmann-Leitner ES, Abrams SI.
    Cancer Immunol Immunother; 2001 Nov 01; 50(9):445-55. PubMed ID: 11761438
    [Abstract] [Full Text] [Related]

  • 4. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ, Butterfield LH, Dissette VB, Economou JS, Bonavida B.
    J Immunol; 2001 Mar 01; 166(5):3564-73. PubMed ID: 11207317
    [Abstract] [Full Text] [Related]

  • 5. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways.
    Yang S, Haluska FG.
    J Immunol; 2004 Apr 01; 172(7):4599-608. PubMed ID: 15034078
    [Abstract] [Full Text] [Related]

  • 6. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.
    J Immunol; 2002 Apr 01; 168(7):3484-92. PubMed ID: 11907109
    [Abstract] [Full Text] [Related]

  • 7. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.
    Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW.
    J Immunol; 2003 Jun 15; 170(12):6338-47. PubMed ID: 12794167
    [Abstract] [Full Text] [Related]

  • 8. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
    Caldwell SA, Ryan MH, McDuffie E, Abrams SI.
    J Immunol; 2003 Sep 01; 171(5):2402-12. PubMed ID: 12928387
    [Abstract] [Full Text] [Related]

  • 9. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma.
    Darcy PK, Kershaw MH, Trapani JA, Smyth MJ.
    Eur J Immunol; 1998 May 01; 28(5):1663-72. PubMed ID: 9603473
    [Abstract] [Full Text] [Related]

  • 10. Bcl-2 protects against Fas-based but not perforin-based T cell-mediated cytolysis.
    Lee RK, Spielman J, Podack ER.
    Int Immunol; 1996 Jul 01; 8(7):991-1000. PubMed ID: 8757944
    [Abstract] [Full Text] [Related]

  • 11. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL.
    Darcy PK, Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ.
    J Immunol; 2000 Apr 01; 164(7):3705-12. PubMed ID: 10725729
    [Abstract] [Full Text] [Related]

  • 12. Characterization of the Fas ligand/Fas-dependent apoptosis of antiretroviral, class I MHC tetramer-defined, CD8+ CTL by in vivo retrovirus-infected cells.
    Rich RF, Green WR.
    J Immunol; 2002 Mar 15; 168(6):2751-8. PubMed ID: 11884442
    [Abstract] [Full Text] [Related]

  • 13. Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes.
    Traidl C, Sebastiani S, Albanesi C, Merk HF, Puddu P, Girolomoni G, Cavani A.
    J Immunol; 2000 Sep 15; 165(6):3058-64. PubMed ID: 10975816
    [Abstract] [Full Text] [Related]

  • 14. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES, Kantor JA, Shupert WL, Schlom J, Abrams SI.
    Cell Immunol; 1998 Aug 01; 187(2):103-16. PubMed ID: 9732698
    [Abstract] [Full Text] [Related]

  • 15. Positive and negative consequences of soluble Fas ligand produced by an antigen-specific CD4(+) T cell response in human carcinoma immune interactions.
    Bergmann-Leitner ES, Abrams SI.
    Cell Immunol; 2001 Apr 10; 209(1):49-62. PubMed ID: 11414736
    [Abstract] [Full Text] [Related]

  • 16. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.
    Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S, Nagai K.
    J Immunol; 1996 May 15; 156(10):3678-86. PubMed ID: 8621902
    [Abstract] [Full Text] [Related]

  • 17. ECH, an epoxycyclohexenone derivative that specifically inhibits Fas ligand-dependent apoptosis in CTL-mediated cytotoxicity.
    Mitsui T, Miyake Y, Kakeya H, Osada H, Kataoka T.
    J Immunol; 2004 Mar 15; 172(6):3428-36. PubMed ID: 15004142
    [Abstract] [Full Text] [Related]

  • 18. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Bhattacharya-Chatterjee M.
    Immunology; 2006 Aug 15; 118(4):483-96. PubMed ID: 16895556
    [Abstract] [Full Text] [Related]

  • 19. IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells.
    Roth E, Pircher H.
    J Immunol; 2004 Feb 01; 172(3):1588-94. PubMed ID: 14734739
    [Abstract] [Full Text] [Related]

  • 20. Essential roles of perforin in antigen-specific cytotoxicity mediated by human CD4+ T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells.
    Yanai F, Ishii E, Kojima K, Hasegawa A, Azuma T, Hirose S, Suga N, Mitsudome A, Zaitsu M, Ishida Y, Shirakata Y, Sayama K, Hashimoto K, Yasukawa M.
    J Immunol; 2003 Feb 15; 170(4):2205-13. PubMed ID: 12574394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.